Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Treat and Extend for Persistent DME
NCT03059277Phase 4Withdrawn
- Sponsor
- Centricity Research
- Start
- Jun 2018
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 4 trial of aflibercept in diabetic macular edema (DME), sponsored by Centricity Research. Planned start Jun 2018; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03059277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03059277.